Pulmatrix (PULM)
NASDAQ:PULM
Want to see PULM full AI Analyst Report?
PULM Stock Chart & Stats
$2.35
-$0.25(-3.99%)
At close: 4:00 PM EST
$2.35
-$0.25(-3.99%)
Day’s Range― - ―
52-Week Range$1.16 - $9.23
Previous CloseN/A
Volume31.27K
Average Volume (3M)7.19K
Market Cap
$5.04M
Enterprise Value$1.75M
Total Cash (Recent Filing)$3.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding3,652,285
10 Day Avg. Volume4,700
30 Day Avg. Volume7,194
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.14
Price to Sales (P/S)0.00
P/FCF Ratio-1.50
Enterprise Value/Market Cap0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-125.19
Enterprise Value/Ebitda-0.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.24
Revenue Forecast (FY)$16.45M
Bulls Say, Bears Say
Bulls Say
Strategic Merger & Capital InfusionThe planned all-stock merger with Eos SENOLYTIX plus ~$19M of concurrent financing is a structural shift: it repositions the company into gerotherapeutics, installs new leadership, and materially strengthens near-term capital availability to advance clinical programs and reduce immediate funding risk over the next several quarters.
Low Leverage / No DebtHaving no recorded debt across recent periods reduces insolvency and interest burden risk, preserving flexibility for equity-based financings or partnerships. This durable balance-sheet characteristic lowers fixed financial obligations and supports strategic options during clinical development cycles.
Clinical-stage Pipeline & Partner BackingA diversified clinical portfolio with a Phase 2‑ready program and a partner-led Phase 3 asset creates multiple, non-correlated value catalysts. Partner advancement of PUR1900 reduces Pulmatrix's cash burden and execution risk while preserving upside from milestone payments, partnerships, or licensing over the medium term.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow of roughly -$4.7M TTM is a durable constraint: it requires repeated external funding to sustain operations and trials, increases dilution risk for shareholders, and limits the firm's ability to self-fund development unless burn declines materially or new capital is secured.
No Sustained RevenueThe absence of current recurring revenue indicates the business remains development-stage and dependent on financing rather than commercial cash flow. This structural lack of operating income reduces predictability of runway, makes investment returns contingent on successful clinical or deal outcomes, and raises funding risk.
Eroded Equity And Asset BaseMaterial declines in shareholders' equity and total assets over several years shrink financial flexibility and the firm's ability to absorb setbacks. Even with zero debt, a diminished asset base reduces collateral for credit, amplifies dilution risk with new financings, and restricts strategic investment capacity going forward.
Pulmatrix News
PULM FAQ
What was Pulmatrix’s price range in the past 12 months?
Pulmatrix lowest stock price was $1.16 and its highest was $9.23 in the past 12 months.
What is Pulmatrix’s market cap?
Pulmatrix’s market cap is $5.04M.
When is Pulmatrix’s upcoming earnings report date?
Pulmatrix’s upcoming earnings report date is Aug 12, 2026 which is in 73 days.
How were Pulmatrix’s earnings last quarter?
Pulmatrix released its earnings results on May 15, 2026. The company reported -$0.321 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.321.
Is Pulmatrix overvalued?
According to Wall Street analysts Pulmatrix’s price is currently Overvalued.
Does Pulmatrix pay dividends?
Pulmatrix does not currently pay dividends.
What is Pulmatrix’s EPS estimate?
Pulmatrix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pulmatrix have?
Pulmatrix has 3,652,285 shares outstanding.
What happened to Pulmatrix’s price movement after its last earnings report?
Pulmatrix reported an EPS of -$0.321 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.575%.
Which hedge fund is a major shareholder of Pulmatrix?
Currently, no hedge funds are holding shares in PULM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pulmatrix
Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma, and in patients with cystic fibrosis; PUR1800, a narrow spectrum kinase inhibitor that is in Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; and PUR3100, an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of Pulmazole; and a collaboration and license agreement with Sensory Cloud, Inc. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
1.84% Mutual Funds
0.56% Other Institutional Investors
96.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---